HERON THERAPEUTICS, INC. /DE/ — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Heron Therapeutics announced Q3 2026 net revenue of $35.3M (down 7.8% from $38.2M in Q3 2025), with ZYNRELEF up 13.8% and APONVIE up 49.3% YoY, but CINVANTI down 16.6%. More significantly, the company entered into a definitive asset purchase agreement whereby CorMedix Therapeutics will acquire substantially all of Heron's assets, subject to stockholder approval and customary closing conditions. Heron ended Q3 with $23.4M in cash and equivalents, and commercial sales of SUSTOL ceased September 30, 2026.
Why this rating
Asset sale represents existential change—company ceasing independent operations. $235M market cap company being acquired whole. Highly significant regardless of deal terms.
Tradability signal
NO TRADE
No trade: price $0.38 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.38 ▲ 2.06% | at our read · unknown $0.37 | +10 min · unknown $0.39 ▲ 5.42% | +30 min · unknown $0.37 ▲ 1.36% | +1 hr · unknown $0.39 ▲ 5.15% | +4 hrs · unknown $0.38 ▲ 2.98% |
The stock had already moved -2.02% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.